Your body creates the healing. We are the catalyst, and the conditions.

INJURY: TERRAIN, THEN THE CATALYST

Our injury page says two clocks start the day you are hurt, and that the one belonging to your tissue is the one nobody manages. This is that clock. It begins with the part most people skip, because it is the part that decides everything the rest of the sequence can achieve.

The premise this practice is built on

Your body creates the healing. The repair is performed by your own cells, out of your own raw material, on your own metabolic budget — and it is a genuinely impressive piece of work when the conditions allow it. What a physician contributes is two things: we optimize the biological environment that repair has to happen in, and we deliver a precise cellular catalyst to the exact structure that needs one.

That is a smaller claim than this field usually makes and it is the one that survives contact with results. It also has a corollary worth hearing before you spend anything. If the terrain stays inflamed, a rigorously prepared, correctly targeted, guideline-compliant biologic will fail — and it will fail quietly, so that the treatment gets blamed instead of the conditions it was asked to work in.

Terrain first, and it is not a lifestyle footnote

The injection is autologous. It is manufactured from you, on the morning of the procedure, out of whatever is circulating. Insulin resistance, chronic inflammatory load, poor sleep, nicotine and vitamin D status are not adjacent concerns in that sentence — they are the manufacturing conditions and the site conditions at once. This is why an evaluation here starts with bloodwork that surprises people, set out on why a pain clinic asks to see your bloodwork.

The published record points in the same direction without ever putting it this way. The systematic review and meta-analysis of risk factors for rotator cuff tendinopathy found systemic and metabolic associations, not only mechanical load. A secondary analysis of a randomized trial found that body mass index predicted outcomes after microfragmented adipose tissue but not after platelet-rich plasma — which is a useful correction to our own instinct, and a reminder that terrain acts through specific mechanisms rather than as a general moral about health. We report that one because it goes against the simple version of our own argument.

None of that is a reason to withhold treatment from anybody. It is a reason to fix what can be fixed before spending a catalyst, and to say out loud which conditions are limiting the ceiling. That conversation belongs before the procedure, not in the follow-up when the result is disappointing.

Then the clock: days one to four

A torn ligament, a strained muscle or a compressed joint surface bleeds. That hematoma is not waste. It is the first delivery of platelets to the site, and the growth factors they release are the opening instruction for everything that follows. Neutrophils arrive, clear damaged material, and hand off to macrophages.

This is the phase people try hardest to shut down, because it is the phase that hurts and swells. Some of that is correct. But a concentrate of platelets injected into a site already saturated with platelets is not adding a signal. It is adding volume to a message the body has already sent, and there is nothing stalled for a catalyst to restart.

Weeks two to six: the phase that sets the ceiling

Fibroblasts lay down type III collagen. It is fast, disorganized, and mechanically inferior to the type I collagen that should eventually replace it. The matrix being built in these weeks is provisional, and it is built in whatever shape the limb is held in and under whatever loads it is asked to carry.

This is the honest reason delay costs something. Nothing dramatic happens on any single day of an unmanaged month. What happens is that six weeks of provisional matrix consolidates around a guarded, unloaded joint, and the ceiling of the eventual result is set lower than it needed to be. No injection recovers that later. Graded loading during this window is the part of the treatment that has no substitute, and it is a treatment, not aftercare.

Six weeks to six months: remodeling, and the fork

Type III collagen is progressively replaced by type I and the fibers align to the direction of load. Two things can happen. The tissue remodels and pain follows it down. Or remodeling stalls: the matrix stays disorganized, small vessels and nerve fibers grow into it, and what began as an injury becomes a tendinopathy or a chronically irritable joint that behaves nothing like the original event.

A stalled repair is the state a catalyst is for, and it is the state the graded evidence was actually built on. Read the inclusion criteria of almost any positive trial in this field and you find persistent symptoms measured in months, not an emergency department visit last Tuesday.

The three decision points

• Around week six. Is this following the normal arc? Pain and function should both be moving. If function is flat while pain improves, something is being avoided rather than restored, and that is worth catching now rather than at month nine.
• Around month three. A stalled repair declares itself here. It is also the earliest point where a catalyst is usually the right conversation — and by then the terrain work started at the first visit has had a quarter to move the numbers it can move.
• Around month six to twelve. Whatever the tissue is going to do on its own, it has largely done. The question changes from whether repair will resume to whether the joint surface is on a degenerative trajectory, which is a different problem set out on the post-traumatic knee page.

The sequencing sentence nobody quotes from the guidelines

Every serious document in this field sequences the treatment the same way, and each does it in its own idiom. The 2025 ASIPP guideline places regenerative therapy after a diagnostic work-up and beside structured exercise, physical therapy and lifestyle management rather than ahead of any of them. Every ESSKA-ICRS scenario rated appropriate belongs to someone who has already been through conservative care. All sixteen questions in the multispecialty guidelines concern persistent presentations, never fresh ones.

Those are not hedges. They are the same statement made in committee language: the injection is a step inside a plan, and the plan is what makes it work. The injection is not the treatment. It is what makes the treatment possible.

Why “can I have it tomorrow” is usually answered no

Not for administrative reasons, and not to make you wait. In the first days after an injury the site is already saturated with platelets and the repair cascade is already running at full volume. A concentrate of the same signal, delivered into the middle of that, is not raising anything. There is nothing stalled for a catalyst to restart.

What that same week does reward is everything else: naming what was injured, starting load correctly while the provisional matrix is still being laid down, and measuring the terrain while there is a full quarter left in which to move it. What that looks like in practice is on the timing page.

Why the terrain question outlives the injury

Roughly 12% of the overall prevalence of symptomatic hip, knee and ankle osteoarthritis in the United States is post-traumatic in origin — on the order of 5.6 million people, and about $3.06 billion a year in direct cost. A single joint injury at thirty-four is a thirty-year question, and the thirty years are spent in the same metabolic environment that decided how the first six months went.

What people ask about recovery after an injury

How long after an injury should I be seen?

Early, and treated on the schedule the tissue is on — those are different things. An early visit establishes what was injured, starts loading correctly during the weeks that set the ceiling, and begins terrain work while there is still time for it to matter. What an evaluation involves is set out separately.

Is there a point where it is too late?

Late is a worse starting position than early and it is not a closed door, because stalled repair and chronic post-traumatic joint pain are exactly what the graded evidence was built on. What changes is the realistic target, which is the distinction drawn on the tendinopathy page.

Why does resting until it settles make things worse?

Because the matrix laid down in weeks two to six consolidates in whatever configuration the limb is held in, so six weeks of guarding produces tissue organized for guarding. Graded loading has no substitute, which is why it is built into the recovery timeline rather than handed out at discharge.

Why does my metabolic health matter for an injury that was somebody else's fault?

Because the injection is made from you and the repair is performed by you, so your inflammatory and metabolic state is both the manufacturing condition and the site condition. Fault decides who pays; terrain decides what heals. What we measure is on the metabolic health page.

Does an injection speed up healing that is already happening?

There is no good evidence that it does, and two placebo-controlled trials in fresh injury found no benefit at all. A catalyst is for a repair that has stopped, not one that is running — the difference between those states is described on the page on how PRP works.

My pain is worse at three months than it was at three weeks. Is that normal?

It is common and worth investigating rather than waiting out, because it is the pattern a stalled repair makes — and also the pattern of a pain generator that was never the structure everyone assumed, which is why a normal scan settles less than people think.

The rest of this thread

• Why we start with your bloodwork
• Too soon, too late, or now
• The knee after a collision
• The neck injury a scanner cannot see
• When the scan is normal and the injury is not
• Injury and work comp: the two clocks